

PATENT
674523-2006.1

In the Claims

1-10. (Cancelled)

11. (Currently amended) The retroviral vector production system according to claim [[10]] 30, wherein the ~~equine non-primate~~ lentivirus is EIAV.

12-15. (Cancelled)

16. (Currently amended) A retroviral particle ~~obtainable comprising a retroviral vector obtained from the retroviral vector production system~~ of claim [[9]] 30.

17. (Currently amended) A cell transfected or transduced with [[a]] the retroviral particle ~~obtainable from the retroviral vector~~ of claim [[9]] 16.

18. (Currently amended) A cell transfected or transduced with a retroviral vector ~~obtained from the retroviral vector production system according to claim~~ [[9]] 30.

19. (Cancelled)

20. (Currently amended) A method for delivery of a nucleotide sequence of interest (NOI) to a target cell comprising introducing a retroviral vector obtained from the retroviral vector production system according to claim [[9]] 30 into the target cell, wherein the retroviral vector comprises an NOI; and whereby the NOI is expressed in the target cell.

21. (Currently amended) A method of transfecting or transducing a cell, comprising contacting said cell with a retroviral vector obtained from the retroviral vector production system according to claim [[9]] 30, wherein said cell is transfected or transduced by said retroviral vector.

22. (Currently amended) A delivery system in the form of a retroviral vector ~~obtained from the retroviral production system according claim~~ [[9]] 30.

23-29. (Cancelled)

30. (New) A non-primate lentivirus-based retroviral vector production system comprising nucleic acid sequence(s) encoding a non-primate lentivirus genome, gag, pol, and an envelope protein, wherein nucleic acid sequence(s) encoding functional Tat are absent from the system.